



1652

# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
[WWW.FULBRIGHT.COM](http://WWW.FULBRIGHT.COM)

GSHISHIMA@FULBRIGHT.COM  
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

January 16, 2003

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 16, 2003

Date

Gina N. Shishima

Commissioner for Patents  
Washington, D.C. 20231

*Re: SN 09/768,877 entitled "METHODS OF TREATMENT OF TYPE 2 DIABETES"  
by Polonsky et al.  
Our ref: ARCD:307USD1/10100104; UC Tech ref: UCHI:790; UT ref: UTH:256*

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) I. Amendment; and II. Response to Office Action Dated October 16, 2002 with Appendices A-F; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/ARCD:307USD1.

Very truly yours,

Gina N. Shishima  
Reg No. 45,104

GS/SF  
Enclosures

RECEIVED  
JAN 22 2003  
TECH CENTER 1600/2900

25252763.1



CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 16, 2003  
\_\_\_\_\_  
Date

Gina Shishima

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Polonsky et. al.

Group Art Unit: 1652

Serial No.: 09/768,877

Examiner: Delia M. Ramirez

Filed: January 23, 2001

Atty. Dkt. No.: ARCD:307/USD1

For: METHODS OF TREATMENT OF TYPE 2  
DIABETES

**I. AMENDMENT; AND II. RESPONSE TO OFFICE ACTION**  
**DATED OCTOBER 16, 2002**

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

JAN 22 2003

TECH CENTER 1600/2900

Commissioner:

This paper is submitted in response to the Office Action dated October 16, 2002 for which the three-month date for response is January 16, 2003.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/ARCD:307USD1.

Reconsideration of the application is respectfully requested.